InvestSMART

Cambium Bio Limited (ASX:CMB)

ALERT: Price-sensitive ASX Announcement for CMB
Current share price for CMB : $0.430 -0.12 (-21.82%)+
Announcement
Release
23 Jan 2026 9:14AM
Price at Release
$0.550
Full Release
download
Summary
Cambium Bio Limited, a clinical-stage regenerative medicine company, released a quarterly cash flow report and business update for the period ending 31 December 2025. The company received a A$0.6 million R&D Tax Incentive refund and announced a strategic investment from ZYBT amounting to A$2.4 million. The net operating cash outflow was A$0.364 million, leading to a closing cash balance of A$0.774 million. Cambium Bio continues preparations for Phase 3 trials of Elate Ocular® and is advancing out-licensing discussions to secure additional funding. The company is pursuing a funding strategy that includes strategic equity investments and licensing deals to support its clinical and corporate milestones.
Key Points
  • Cambium Bio Limited is focused on developing biologics for ophthalmology and tissue repair.
  • Received a A$0.6 million R&D Tax Incentive refund for FY2025.
  • ZYBT committed to a A$2.4 million strategic investment.
  • Net operating cash outflow was A$0.364 million.
  • Total closing cash balance of A$0.774 million as of 31 December 2025.
  • Ongoing preparations for pivotal Phase 3 trials of Elate Ocular®.
  • Focused on advancing licensing discussions in Europe and the Middle East.
  • Multi-pronged funding strategy includes ZYBT placement and licensing transactions.
  • Commitment to advancing clinical pipeline and commercialization.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.